FINWIRES · TerminalLIVE
FINWIRES

Delta-Fly Pharma Completes Patient Enrolment in Phase 2 Portion of Pancreatic Cancer Study

By

Biotech firm Delta-Fly Pharma (TYO:4598) has completed patient enrolment for the phase 2 portion of its clinical trial testing an experimental drug for pancreatic cancer, according to a Tokyo bourse filing on Thursday.

The study, known as DFP-17729, is a double-blind, randomised, placebo-controlled trial that combines the company's drug with TS-1, an existing oral chemotherapy, in patients with advanced or recurrent pancreatic cancer that cannot be surgically removed.

The trial uses an adaptive design, meaning the results from the phase 2 portion will determine how many patients are needed for the phase 3 portion. If the drug shows a clear benefit in overall survival, the study can move quickly into the next phase.

If successful, DFP-17729 could offer patients a new treatment option that is taken orally, has a strong safety profile, and is cost-effective. The drug works by neutralising the acidic environment around tumours, which helps slow cancer growth without the serious side effects often seen with other treatments.

Related Articles

Asia

Chasen's Profit Slips in Fiscal H2; Shares Surge 11%

Chasen (SGX:5NV) booked a 1% decline in its profit in the fiscal second half ended March 31 of SG$6.4 million, from a profit of SG$6.5 million a year earlier, according to a Thursday filing with the Singapore Exchange.Earnings per share slid to SG$0.0168 from SG$0.0181 in the year-ago period.Revenue jumped 20% year over year to SG$67.8 million from SG$56.6 million.Shares of the global integrated logistics service provider zoomed over 11% in recent trade.

SGX:5NV
Asia

Risecomm Group Enters Debt Swap Agreements With Creditors; Shares Jump 65%

Risecomm Group (HKG:1679) entered into an agreement with some creditors to issue a mix of debt and equity to settle outstanding loans, according to a Wednesday filing with the Hong Kong bourse.The power line communication products provider's shares gained 69% in late-morning trade Thursday.The firm will issue 69.8 million shares priced at HK$0.46 apiece and three-year convertible bonds worth HK$128.5 million to the creditors.The company simultaneously launched a public offering to raise funds to settle certain other loans.The firm is seeking investors for 85.9 million shares priced at HK$0.46 each, or HK$39.5 million in total, which will be used to repay loans owed to Fu Xiaoqin, a shareholder, and an entity identified as Clear Jolly.The transactions are subject to shareholder approval.

HKG:1679
Asia

Aussie Broadband Makes International Mobile Roaming Available for Mobile Customers

Aussie Broadband (ASX:ABB) said international mobile roaming is now available for Aussie Broadband mobile customers under new updates being rolled out to the MyAussie and Carbon portals, according to a statement on Thursday.Customers will be able to access 5 gigabytes of data and unlimited calls and texts for AU$5 per day when travelling in Zone 1 countries without switching or acquiring a new SIM card or provider. For customers travelling in Zone 2 and Zone 3 countries, roaming prices will be charged at pay-as-you-go rates.Customers can also choose to opt out of international mobile roaming at any time, either directly through the app or by contacting Aussie Broadband's customer service.Its shares fell 1% in recent trading on Thursday.

ASX:ABB